On Tuesday, BIO Ventures for Global Health (BVGH) announced the completion of the 30th research agreement as part of its partnership with the World Intellectual Property Organization (WIPO) to better enable drug companies to assist researchers in addressing infectious diseases worldwide. The partnership aims to accelerate development of drugs, diagnostics and vaccines for more than 1.5 billion people suffering from malaria, tuberculosis, and other neglected tropical diseases including dengue in developing nations.
A recent publication in Nature reports scientists have seriously underestimated the global incidence of dengue. There have been outbreaks of dengue even in developed nations including Portugal, Russia and smaller ones in the U.S. The study predicts there could be as many as 400 million cases of dengue each year.
BVGH President Jennifer Dent remarked, “WIPO Re:Search partnerships are advancing the development of new products to address these old and debilitating diseases. Working with our members and partners BVGH plans to broaden these agreements and establish new programs to address the needs of infectious disease researchers worldwide.”
For more information, please read the BVGH press release.